{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:58Z","timestamp":1786982758269,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s40265-017-0730-4","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T05:07:53Z","timestamp":1490850473000},"page":"765-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"77","author":[{"given":"Alicia C.","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga P.","family":"Nyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"McNicholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"730_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288","author":"P Malfertheiner","year":"2016","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence Consensus Report. Gut. 2016;. doi:\n                        10.1136\/gutjnl-2016-312288\n                        \n                    .","journal-title":"Gut"},{"key":"730_CR2","doi-asserted-by":"publisher","unstructured":"Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016;151(1):51\u201369 e14. doi:\n                        10.1053\/j.gastro.2016.04.006\n                        \n                    .","DOI":"10.1053\/j.gastro.2016.04.006"},{"key":"730_CR3","doi-asserted-by":"publisher","unstructured":"Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. IV Spanish consensus conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol. 2016. doi:\n                        10.1016\/j.gastrohep.2016.05.003\n                        \n                    .","DOI":"10.1016\/j.gastrohep.2016.05.003"},{"issue":"11\u201312","key":"730_CR4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/j.1365-2036.2011.04887.x","volume":"34","author":"JP Gisbert","year":"2011","unstructured":"Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011;34(11\u201312):1255\u201368. doi:\n                        10.1111\/j.1365-2036.2011.04887.x\n                        \n                    .","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"730_CR5","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","volume":"102","author":"WD Chey","year":"2007","unstructured":"Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808\u201325. doi:\n                        10.1111\/j.1572-0241.2007.01393.x\n                        \n                    .","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"730_CR6","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/jgh.12984","volume":"30","author":"JS Kim","year":"2015","unstructured":"Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30(9):1338\u201345. doi:\n                        10.1111\/jgh.12984\n                        \n                    .","journal-title":"J Gastroenterol Hepatol."},{"key":"730_CR7","doi-asserted-by":"publisher","unstructured":"Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016(6):CD009034. doi:\n                        10.1002\/14651858.CD009034.pub2\n                        \n                    .","DOI":"10.1002\/14651858.CD009034.pub2"},{"key":"730_CR8","doi-asserted-by":"publisher","unstructured":"Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104(12):3069\u201379. doi:\n                        10.1038\/ajg.2009.555\n                        \n                    . (quiz 1080)","DOI":"10.1038\/ajg.2009.555"},{"issue":"19","key":"730_CR9","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.3748\/wjg.v22.i19.4766","volume":"22","author":"ZQ Song","year":"2016","unstructured":"Song ZQ, Zhou LY. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2016;22(19):4766\u201375. doi:\n                        10.3748\/wjg.v22.i19.4766\n                        \n                    .","journal-title":"World J Gastroenterol."},{"issue":"6","key":"730_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1365-2036.2011.04770.x","volume":"34","author":"JP Gisbert","year":"2011","unstructured":"Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011;34(6):604\u201317. doi:\n                        10.1111\/j.1365-2036.2011.04770.x\n                        \n                    .","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"730_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1136\/gut.2003.022111","volume":"53","author":"F Megraud","year":"2004","unstructured":"Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374\u201384. doi:\n                        10.1136\/gut.2003.022111\n                        \n                    .","journal-title":"Gut."},{"issue":"Suppl 1","key":"730_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.0953-0673.2004.01831.x","volume":"19","author":"D Forman","year":"2004","unstructured":"Forman D, Graham DY. Review article: impact of Helicobacter pylori on society-role for a strategy of \u2018search and eradicate\u2019. Aliment Pharmacol Ther. 2004;19(Suppl 1):17\u201321.","journal-title":"Aliment Pharmacol Ther."},{"issue":"35","key":"730_CR13","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.3748\/wjg.14.5385","volume":"14","author":"JP Gisbert","year":"2008","unstructured":"Gisbert JP. \u201cRescue\u201d regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14(35):5385\u2013402.","journal-title":"World J Gastroenterol."},{"issue":"5","key":"730_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection\u2014the Maastricht IV\/Florence Consensus Report. Gut. 2012;61(5):646\u201364. doi:\n                        10.1136\/gutjnl-2012-302084\n                        \n                    .","journal-title":"Gut."},{"issue":"6","key":"730_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1046\/j.1365-2036.2002.01276.x","volume":"16","author":"JP Gisbert","year":"2002","unstructured":"Gisbert JP, Pajares JM. Review article: Helicobacter pylori \u201crescue\u201d regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16(6):1047\u201357.","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"730_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/apt.13712","volume":"44","author":"PY Chen","year":"2016","unstructured":"Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;44(5):427\u201337. doi:\n                        10.1111\/apt.13712\n                        \n                    .","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"730_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1572-0241.2003.t01-1-07288.x","volume":"98","author":"L Laine","year":"2003","unstructured":"Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter. North American trial. Am J Gastroenterol. 2003;98(3):562\u20137.","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"730_CR18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:\n                        10.1371\/journal.pmed.1000097\n                        \n                    .","journal-title":"PLoS Med."},{"key":"730_CR19","unstructured":"Review Manager (RevMan) (computer program). Version 5.3. Copenhagen: The Nordic Cochrane Centre TCC, 2014."},{"key":"730_CR20","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:\n                        10.1136\/bmj.i4919\n                        \n                    .","journal-title":"BMJ"},{"issue":"4","key":"730_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380\u20132. doi:\n                        10.1016\/j.jclinepi.2010.09.011\n                        \n                    .","journal-title":"J Clin Epidemiol"},{"key":"730_CR22","doi-asserted-by":"publisher","unstructured":"Gisbert JP, Molina-Infante J, Marin AC, Rodriguez GV, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple \u201csequential\u201d or \u201cconcomitant\u201d treatment to eradicate H. pylori infection. Gastroenterology 2014;146(5 suppl. 1):S-394.","DOI":"10.1016\/S0016-5085(14)61419-0"},{"issue":"6","key":"730_CR23","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3109\/00365521.2013.786132","volume":"48","author":"JP Gisbert","year":"2013","unstructured":"Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple \u201csequential\u201d or \u201cconcomitant\u201d treatment to eradicate H. pylori infection. Scand J Gastroenterol. 2013;48(6):652\u20136. doi:\n                        10.3109\/00365521.2013.786132\n                        \n                    .","journal-title":"Scand J Gastroenterol."},{"issue":"1","key":"730_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/hel.12085","volume":"19","author":"PI Hsu","year":"2014","unstructured":"Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, et al. Ten-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter. 2014;19(1):74\u20139. doi:\n                        10.1111\/hel.12085\n                        \n                    .","journal-title":"Helicobacter."},{"issue":"6","key":"730_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.5009\/gnl13303","volume":"8","author":"KH Chung","year":"2014","unstructured":"Chung KH, Lee DH, Jin E, Cho Y, Seo JY, Kim N, et al. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea. Gut Liver. 2014;8(6):605\u201311. doi:\n                        10.5009\/gnl13303\n                        \n                    .","journal-title":"Gut Liver."},{"issue":"22","key":"730_CR26","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.3748\/wjg.v20.i22.6932","volume":"20","author":"KK Kang","year":"2014","unstructured":"Kang KK, Lee DH, Oh DH, Yoon H, Shin CM, Park YS, et al. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol. 2014;20(22):6932\u20138. doi:\n                        10.3748\/wjg.v20.i22.6932\n                        \n                    .","journal-title":"World J Gastroenterol."},{"issue":"46","key":"730_CR27","doi-asserted-by":"publisher","first-page":"13124","DOI":"10.3748\/wjg.v21.i46.13124","volume":"21","author":"JH Lim","year":"2015","unstructured":"Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, et al. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol. 2015;21(46):13124\u201331. doi:\n                        10.3748\/wjg.v21.i46.13124\n                        \n                    .","journal-title":"World J Gastroenterol."},{"issue":"1 Suppl. 1","key":"730_CR28","first-page":"A271","volume":"1","author":"A Campillo","year":"2013","unstructured":"Campillo A, Amorena E, Ostiz M. Local experience with non-bismuth quadruple therapy as first line treatment for helicobacter pylori eradication. United Eur Gastroenterol J. 2013;1(1 Suppl. 1):A271.","journal-title":"United Eur Gastroenterol J."},{"key":"730_CR29","unstructured":"Cerqueira R, Correia M, Vilar H, Conceicao Manso M. Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery. United Eur Gastroenterol J. 2015;3(5 suppl. 1):A496."},{"issue":"6","key":"730_CR30","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/hel.12062","volume":"18","author":"SD Georgopoulos","year":"2013","unstructured":"Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter. 2013;18(6):459\u201367. doi:\n                        10.1111\/hel.12062\n                        \n                    .","journal-title":"Helicobacter."},{"key":"730_CR31","doi-asserted-by":"publisher","unstructured":"Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D\u2019Ambrosio P, Castorani L, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol. 2013;37(6):647\u201350. doi:\n                        10.1016\/j.clinre.2013.04.003\n                        \n                    .","DOI":"10.1016\/j.clinre.2013.04.003"},{"issue":"2","key":"730_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2217\/14750708.3.2.251","volume":"3","author":"A Zullo","year":"2006","unstructured":"Zullo A, de Francesco V, Panella C, Morini S, Ierardi E. Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. Therapy. 2006;3(2):251\u20134.","journal-title":"Therapy."},{"key":"730_CR33","doi-asserted-by":"publisher","unstructured":"Manfredi M, Bizzarri B, de\u2019Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter 2012;17(4):246\u201353. doi:\n                        10.1111\/j.1523-5378.2012.00945.x\n                        \n                    .","DOI":"10.1111\/j.1523-5378.2012.00945.x"},{"issue":"11","key":"730_CR34","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.dld.2007.06.016","volume":"39","author":"F Perna","year":"2007","unstructured":"Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39(11):1001\u20135. doi:\n                        10.1016\/j.dld.2007.06.016\n                        \n                    .","journal-title":"Dig Liver Dis."},{"issue":"8","key":"730_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.dld.2009.12.007","volume":"42","author":"S Pontone","year":"2010","unstructured":"Pontone S, Standoli M, Angelini R, Pontone P. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. Dig Liver Dis. 2010;42(8):541\u20133. doi:\n                        10.1016\/j.dld.2009.12.007\n                        \n                    .","journal-title":"Dig Liver Dis."},{"issue":"2","key":"730_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.dld.2014.10.009","volume":"47","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Romano M, Molina-Infante J, Lucendo AJ, Medina E, Modolell I, et al. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis. 2015;47(2):108\u201313. doi:\n                        10.1016\/j.dld.2014.10.009\n                        \n                    .","journal-title":"Dig Liver Dis."},{"issue":"8","key":"730_CR37","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/apt.13128","volume":"41","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Romano M, Gravina AG, Solis-Munoz P, Bermejo F, Molina-Infante J, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41(8):768\u201375. doi:\n                        10.1111\/apt.13128\n                        \n                    .","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"730_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.dld.2016.01.002","volume":"48","author":"Z Song","year":"2016","unstructured":"Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Dig Liver Dis. 2016;48(5):506\u201311. doi:\n                        10.1016\/j.dld.2016.01.002\n                        \n                    .","journal-title":"Dig Liver Dis."},{"issue":"9862","key":"730_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","volume":"381","author":"JM Liou","year":"2013","unstructured":"Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381(9862):205\u201313. doi:\n                        10.1016\/S0140-6736(12)61579-7\n                        \n                    .","journal-title":"Lancet."},{"issue":"7","key":"730_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1517\/14656566.2013.782286","volume":"14","author":"AC Marin","year":"2013","unstructured":"Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14(7):843\u201361. doi:\n                        10.1517\/14656566.2013.782286\n                        \n                    .","journal-title":"Expert Opin Pharmacother."},{"issue":"10","key":"730_CR41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrgastro.2010.131","volume":"7","author":"P Malfertheiner","year":"2010","unstructured":"Malfertheiner P. Infection: bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol. 2010;7(10):538\u20139. doi:\n                        10.1038\/nrgastro.2010.131\n                        \n                    .","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"5","key":"730_CR42","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/hel.12052","volume":"18","author":"J Liao","year":"2013","unstructured":"Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18(5):373\u20137. doi:\n                        10.1111\/hel.12052\n                        \n                    .","journal-title":"Helicobacter."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0730-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0730-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0730-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T09:28:42Z","timestamp":1492853322000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0730-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0730-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}